Market revenue in 2023 | USD 10.2 million |
Market revenue in 2030 | USD 25.3 million |
Growth rate | 13.9% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 59.8% in 2023. Horizon Databook has segmented the Argentina head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Constant developments by market players, such as geographic expansion and new product launches, have contributed to Argentina’s market growth. Furthermore, the considerable prevalence of head and neck cancer, coupled with rising demand for advanced therapeutics, is expected to boost market growth over the forecast period.
There has been a steady rise in the number of oncologists in recent years, especially in Brazil and Argentina, as well as increase in awareness about the scarcity of cancer specialists in the region. To enhance & promote the activities in the region, a regional facility has been established at the National Cancer Institute of Argentina (Instituto Nacional del Cáncer de Argentina) in Buenos Aires.
Furthermore, the country annually attracts several international medical tourists seeking non-conventional treatments. The Unique Reimbursement System (SUR, after its acronym in Spanish) is described in SSS Regulation No. 1,200/2012, as amended and supplemented, and is meant to provide financial support to Health Insurance Agents in the reimbursement of specific treatments of diseases with high economic impact, long-term treatment requirements, and low incidence.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Argentina head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account